NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the proposed acquisition of the company by Cytocom, Inc. Cleveland BioLabs stockholders are expected to own 39% of the combined company. The Transaction is expected to close in the first quarter of 2021.
If you are a stockholder of Cleveland BioLabs, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/cbli/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at firstname.lastname@example.org, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
SOURCE Rowley Law PLLC